FIELD OF THE INVENTION
[0001] The present invention relates to a method for preparing a pyrimidone heteroaryl derivative,
and an intermediate for preparing a pyrimidone heteroaryl derivative.
BACKGROUND OF THE INVENTION
[0002] Endometriosis is a common estrogen-dependent gynecological disease, which often occurs
in women of childbearing age, though the action mechanism of which is unclear. The
difficult diagnosis and unclear pathogenesis of endometriosis severely hinder the
discovery of effective treatments. At present, endometriosis is mainly diagnosed by
laparoscopy, and treated by surgery, or controlled by taking contraceptives, GnRH
receptor agonists or progestogen to reduce estrogen levels in the body.
[0003] Gonadotropin releasing hormone (Gonadoliberin; GnRH), also known as luteinizing hormone
releasing hormone (LHRH), is a decapeptide hormone (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2)
synthesized by hypothalamic neuroendocrine cells, and is a central regulatory factor
of the endocrine and reproductive systems. GnRH plays an important role in the hypothalamus-pituitary-gonadal
axis system by being transported to the pituitary through the hypothalamic pituitary
portal circulation system and then binding to GnRH receptor cells in the anterior
pituitary, by promoting the secretion and release of gonadotropin hormones, such as
luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and by regulating
normal development of the ovary and corpus luteum. GnRH receptor plays its regulatory
role by coupling with G protein that can activate the second messenger system of calcium
phosphatidylinositol. LH regulates the production of sex steroids, while FSH regulates
male spermatogenesis and female follicular development.
[0004] WO2015062391A1 (publication date: 7 May 2015) discloses a class of small molecule GnRH receptor
antagonist useful in treating endometriosis, uterine fibroids and prostate cancer,
and its chemical name is 1-(4-(7-(2,6-difluorobenzyl)-3-((dimethyla mino)methyl)-5-(6-methoxypyridazin-3-yl)-4,6-dioxo-4,5,6,7-tetrahydro-2
H -pyrazolo[3,4-
d]pyrimidin-2-yl)phenyl)-3-methoxyurea. This compound has a good activity and can effectively
treat the endocrine and reproductive system diseases, and its structure is shown in
formula (I-1),

[0005] Example 11 of
WO2015062391A1 discloses a method for preparing the compound of formula (1-1) in a total of five
steps, and the specific reactions are as follows:

[0006] The method has problems such as small batch size, thin layer chromatography purification
in post-treatment, low yield and the like. The yield of compound 9d is 69%, and the
yield of product 11 in the last step is only 24.7%, which are not conducive to industrial
production. In addition, hydrochloric acid is added in the post-treatment of prepared
9e, resulting in chlorinated impurities that are hard to remove. It is necessary to
improve this preparation method.
SUMMARY OF THE INVENTION
[0007] The technical problem to be solved by the present invention is to provide a method
for preparing a compound of formula (I) that is different from the prior art, by changing
the starting materials and intermediates to prepare the target product. The preparation
method is optimized through the routes, for example, the reaction steps are shortened,
the reactants such as starting materials are simple and easy to purchase, the reaction
conditions are simple and controllable, the post-treatment is simple, and the yield
is thus improved. The method is conducive to industrial production.
[0008] The technical solutions of the present invention are as follows:
The present invention provides a method for preparing a compound of formula (I) or
a stereoisomer thereof, characterized in that the method comprises a step of reacting
a compound of formula (III), a salt thereof or a stereoisomer thereof with a compound
of formula (II) or a salt thereof to obtain the compound of formula (I),

wherein,
when G is N, D is C, and E is -CH-;
when G is C, D and E are N, or D is C and E is S;
R1 is selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl
and -OR5, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently
and optionally further substituted by one or more substituents selected from the group
consisting of halogen, cyano, nitro, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl,
cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR5, -C(O)OR5, -OC(O)R5, -NHS(O)mR5, -C(O)R5, -NHC(O)R5, -NHC(O)OR5, -NR6R7, -OC(O)NR6R7, -C(O)NR6R7, -NHC(O)NHR5 and -NHC(O)NHOR5;
R2 is alkyl, wherein the alkyl is further substituted by one or more substituents selected
from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl
are optionally further substituted by one or more substituents selected from the group
consisting of halogen, alkyl, haloalkyl, cyano, nitro, -C(O)OR5, -C(O)NR6R7, -OC(O)NR6R7, -OR5, -NHS(O)mR5, -NHC(O)R5 and -NR6R7, wherein the haloalkyl is preferably trifluoromethyl;
R3 is alkyl;
R4 is selected from the group consisting of hydrogen, cycloalkyl, heterocyclyl, aryl,
heteroaryl, -OR5, -NR6R7 and -NR6S(O)mR5, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally
further substituted by one or more substituents selected from the group consisting
of halogen, oxo, alkyl, haloalkyl, hydroxyalkyl, -OR5, -C(O)OR5, -OC(O)R5, -NR7S(O)mR5, -S(O)mR5, -C(O)R5 and -NHC(O)R5;
R5 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclyl,
aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl
are each independently and optionally further substituted by one or more substituents
selected from the group consisting of alkyl, halogen, hydroxy, alkoxy, haloalkoxy,
cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxy and alkoxycarbonyl;
R6 and R7 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl,
heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl
and heteroaryl are each independently and optionally further substituted by one or
more substituents selected from the group consisting of alkyl, halogen, hydroxy, alkoxy,
haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxy and alkoxycarbonyl;
or, R6 and R7 together with the nitrogen atom to which they are attached form a heterocyclyl, wherein
the heterocyclyl contains one or more heteroatoms selected from the group consisting
of N, O and S(O)m, and the heterocyclyl is optionally further substituted by one or more substituents
selected from the group consisting of alkyl, halogen, hydroxy, alkoxy, haloalkoxy,
cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxy and alkoxycarbonyl;
Ra is alkyl, wherein the alkyl is optionally further substituted by one or more substituents
selected from the group consisting of alkyl, halogen, hydroxy, alkoxy, cycloalkyl,
heterocyclyl, aryl, heteroaryl, carboxy and alkoxycarbonyl;
m is 0, 1 or 2; and
n is 1, 2, 3 or 4.
[0009] In the above scheme, the method also comprises steps of

wherein, n, D, E, G, R
1, R
2, R
3, and R
4 are as defined in formula (I);
the compound of formula (VI) is a mono-metal alkoxide or a bi-metal alkoxide, M is
selected from the group consisting of monovalent metal cation, divalent metal cation,
trivalent metal cation and tetravalent metal cation, preferably sodium ion, potassium
ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion, copper ion,
zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon ion, and
more preferably sodium ion; and X is a halogen, and preferably fluorine, chlorine
or bromine.
[0010] In the above scheme, the method further comprises a step of reacting a compound of
formula (VII) with a metal alkoxide to obtain a compound of formula (VI)

wherein, n, D, E, G, R
1, R
3, and R
4 are as defined in formula (I);
R
b is alkyl;
the compound of formula (VI) is a mono-metal alkoxide or a bi-metal alkoxide, M is
selected from the group consisting of monovalent metal cation, divalent metal cation,
trivalent metal cation and tetravalent metal cation, preferably sodium ion, potassium
ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion, copper ion,
zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon ion, and
more preferably sodium ion.
[0011] In fact, the above structure of the compound of formula (VI) is a simplified structure,
and the structure of the compound of formula (VI) can also be

or

wherein, p is 1, 2, 3 or 4, p' is 4 or 9, o is 2, 3 or 4, M and M' are different and
are each selected from the group consisting of monovalent metal cation, divalent metal
cation, trivalent metal cation and tetravalent metal cation, preferably sodium ion,
potassium ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion,
copper ion, zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon
ion, and more preferably sodium ion.
[0012] The present invention provides a method for preparing a compound of formula (1-1),
characterized in that the method is as follows:

[0013] In the above scheme, the method also comprises steps of:

the compound of formula (VI-1) is a mono-metal alkoxide or a bi-metal alkoxide, M
is selected from the group consisting of monovalent metal cation, divalent metal cation,
trivalent metal cation and tetravalent metal cation, preferably sodium ion, potassium
ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion, copper ion,
zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon ion, and
more preferably sodium ion.
[0014] In the above scheme, the method also comprises a step of reacting a compound of formula
(VII-1) with a metal alkoxide to obtain a compound of formula (VI-1)

[0015] Preferably, no acid is added in the post-treatment step of the method, the acid is
selected from the group consisting of an organic acid and an inorganic acid, the organic
acid is preferably trifluoroacetic acid or acetic acid, and the inorganic acid is
preferably hydrochloric acid.
[0016] The present invention also provides a compound of formula (VI)

or a salt thereof or a stereoisomer thereof,
wherein, n, D, E, G, R
1, R
3, and R
4 are as defined in formula (I);
the compound of formula (VI) is a mono-metal alkoxide or a bi-metal alkoxide, M is
selected from the group consisting of monovalent metal cation, divalent metal cation,
trivalent metal cation and tetravalent metal cation, preferably sodium ion, potassium
ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion, copper ion,
zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon ion, and
more preferably sodium ion.
[0017] Preferably, the compound is

[0018] More preferably, the compound is

[0019] The present invention provides a method for preparing a compound of formula (VI),
characterized in that the method is a reaction of a compound of formula (VII) with
a metal alkoxide to obtain the compound of formula (VI)

wherein, n, D, E, G, R
1, R
3, and R
4 are as defined in formula (I);
R
b is alkyl;
the compound of formula (VI) is a mono-metal alkoxide or a bi-metal alkoxide, M is
selected from the group consisting of monovalent metal cation, divalent metal cation,
trivalent metal cation and tetravalent metal cation, preferably sodium ion, potassium
ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion, copper ion,
zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon ion, and
more preferably sodium ion.
[0020] The present invention also provides a method for preparing a compound of formula
(VI-1), characterized in that the method is a reaction of a compound of formula (VII-1)
with a metal alkoxide to obtain the compound of formula (VI-1)

wherein, the compound of formula (VI-1) is a mono-metal alkoxide or a bi-metal alkoxide,
M is selected from the group consisting of monovalent metal cation, divalent metal
cation, trivalent metal cation and tetravalent metal cation, preferably sodium ion,
potassium ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion,
copper ion, zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon
ion, and more preferably sodium ion.
[0021] In the above scheme, no acid is added in the post-treatment step of the method, the
acid is selected from the group consisting of an organic acid and an inorganic acid,
the organic acid is preferably trifluoroacetic acid or acetic acid, and the inorganic
acid is preferably hydrochloric acid.
[0022] In fact, the above structure of the compound of formula (VI-1) is a simplified structure,
and the structure of the compound of formula (VI) can also be

or

wherein, p is 1, 2, 3 or 4, p' is 4 or 9, o is 2, 3 or 4, M and M' are different and
are each selected from the group consisting of monovalent metal cation, divalent metal
cation, trivalent metal cation and tetravalent metal cation, preferably sodium ion,
potassium ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion,
copper ion, zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon
ion, and more preferably sodium ion.
[0023] Preferably, the method is as follows:

[0024] The present invention also provides a method for preparing a compound of formula
(I-1), characterized in that the method is as follows:

[0025] In the above scheme, no acid is added in the post-treatment step of the method for
preparing the compound of formula (VI-1-1) from the compound of formula (VII-1), the
acid is selected from the group consisting of an organic acid and an inorganic acid,
the organic acid is preferably trifluoroacetic acid or acetic acid, and the inorganic
acid is preferably hydrochloric acid.
[0026] The present invention also provides a method for preparing a compound of formula
(1-2), characterized in that the method is as follows:

[0027] In the above scheme, the method also comprises steps of:

the compound of formula (VI-2) is a mono-metal alkoxide or a bi-metal alkoxide, M
is selected from the group consisting of monovalent metal cation, divalent metal cation,
trivalent metal cation and tetravalent metal cation, preferably sodium ion, potassium
ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion, copper ion,
zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon ion, and
more preferably sodium ion.
[0028] In the above scheme, the method also comprises a step of:

[0029] Preferably, no acid is added in the post-treatment step of the method, the acid is
selected from the group consisting of an organic acid and an inorganic acid, the organic
acid is preferably trifluoroacetic acid or acetic acid, and the inorganic acid is
preferably hydrochloric acid.
[0030] In fact, the above structure of the compound of formula (VI-2) is a simplified structure,
and the structure of the compound of formula (VI) can also be

or

wherein, p is 1, 2, 3 or 4, p' is 4 or 9, o is 2, 3 or 4, M and M' are different and
are each selected from the group consisting of monovalent metal cation, divalent metal
cation, trivalent metal cation and tetravalent metal cation, preferably sodium ion,
potassium ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion,
copper ion, zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon
ion, and more preferably sodium ion.
[0031] The present invention also provides a method for preparing a compound of formula
(1-2), characterized in that the method is as follows:

[0032] In the above scheme, no acid is added in the post-treatment step of the method for
preparing the compound of formula (VI-2-1) from the compound of formula (VII-2), the
acid is selected from the group consisting of an organic acid and an inorganic acid,
the organic acid is preferably trifluoroacetic acid or acetic acid, and the inorganic
acid is preferably hydrochloric acid.
[0033] The present invention also provides a method for preparing a compound of formula
(1-3), characterized in that the method is as follows:

[0034] In the above scheme, the method also comprises steps of:

the compound of formula (VI-3) is a mono-metal alkoxide or a bi-metal alkoxide, M
is selected from the group consisting of monovalent metal cation, divalent metal cation,
trivalent metal cation and tetravalent metal cation, preferably sodium ion, potassium
ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion, copper ion,
zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon ion, and
more preferably sodium ion.
[0035] In the above scheme, the method also comprises a step of

[0036] Preferably, no acid is added in the post-treatment step of the method, the acid is
selected from the group consisting of an organic acid and an inorganic acid, the organic
acid is preferably trifluoroacetic acid or acetic acid, and the inorganic acid is
preferably hydrochloric acid.
[0037] In fact, the above structure of the compound of formula (VI-3) is a simplified structure,
and the structure of the compound of formula (VI) can also be

or

wherein, p is 1, 2, 3 or 4, p' is 4 or 9, o is 2, 3 or 4, M and M' are different and
are each selected from the group consisting of monovalent metal cation, divalent metal
cation, trivalent metal cation and tetravalent metal cation, preferably sodium ion,
potassium ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion,
copper ion, zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon
ion, and more preferably sodium ion.
[0038] The present invention also provides a method for preparing a compound of formula
(1-3), characterized in that the method is as follows:

[0039] In the above scheme, no acid is added in the post-treatment step of the method for
preparing the compound of formula (VI-3-1) from the compound of formula (VII-3), the
acid is selected from the group consisting of an organic acid and an inorganic acid,
the organic acid is preferably trifluoroacetic acid or acetic acid, and the inorganic
acid is preferably hydrochloric acid.
[0040] A method for preparing a pharmaceutically acceptable salt of a compound of formula
(I-1), formula (1-2) or formula (1-3), comprises the step(s) in the above schemes,
and a step of reacting the compound of formula (I-1), formula (I-2) or formula (1-3)
with an acid to obtain the pharmaceutically acceptable salt thereof, wherein the acid
is selected from the group consisting of an organic acid and an inorganic acid, and
preferably an organic acid; the organic acid is selected from the group consisting
of acetic acid, maleic acid, fumaric acid, methanesulfonic acid, benzenesulfonic acid
and
p-toluenesulfonic acid, and preferably acetic acid; and the inorganic acid is selected
from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid and
phosphoric acid.
DETAILED DESCRIPTION OF THE INVENTION
[0041] In order to understand the present invention more easily, certain technical and scientific
terms are specifically defined below. Unless otherwise definitely and obviously defined
in this document, all other technical and scientific terms used herein have the meaning
commonly understood by one of ordinary skill in the art to which the present invention
belongs.
[0042] The term "halogen" or "halogen atom" used in the present invention refers to fluorine,
chlorine, bromine or iodine.
[0043] The term "alkyl" used in the present invention refers to a linear or branched alkyl
having 1 to 20 carbon atoms, including for example "C
1-6 alkyl", "C
1-4 alkyl" and the like. The specific examples of alkyl include, but are not limited
to: methyl, ethyl,
n-propyl, isopropyl,
n-butyl, isobutyl,
sec-butyl,
tert-butyl,
n-pentyl, isopentyl, 2-methylbutyl,
neo-pentyl, 1-ethylpropyl,
n-hexyl, isohexyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl,
2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl,
2-ethylbutyl, 1,2-dimethylpropyl and the like.
[0044] The term "alkenyl" used in the present invention refers to a linear or branched group
having 2 to 20 carbon atoms and at least one carbon-carbon double bond, including
for example "C
2-6 alkenyl", "C
2-4 alkenyl" and the like. The examples of alkenyl include, but are not limited to: vinyl,
propenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, and the like.
[0045] The term "alkynyl" used in the present invention refers to a linear or branched group
having 2 to 20 carbon atoms and at least one carbon-carbon triple bond, including
for example "C
2-6 alkynyl", "C
2-4 alkynyl" and the like. The examples of alkynyl include, but are not limited to: ethynyl,
propynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, 4-methyl-2-pentynyl, 2-hexynyl, 3-hexynyl,
5-methyl-2-hexynyl and the like.
[0046] The term "haloalkyl" used in the present invention refers to a group derived from
an "alkyl" in which one or more hydrogen atoms are substituted by one or more "halogen
atoms", and the terms "halogen atom" and "alkyl" are as defined above.
[0047] The term "hydroxy alkyl or hydroxyalkyl" used in the present invention refers to
a group derived from an "alkyl" in which one or more hydrogen atoms are substituted
by one or more "hydroxy", and the term "alkyl" is as defined above.
[0048] The term "alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkoxycarbonyl, carbonylalkoxy,
alkylcarbonylamino, alkylaminocarbonyl, alkylamino, dialkylamino, alkylsulfonylamino
or alkylsulfonyl" used in the present invention refer to a group with a linkage form
of alkyl-O-, haloalkyl-O-, alkyl-C(O)-, alkyl-O-C(O)-, C(O)-alkyl-O-, alkyl-C(O)-NH-,
alkyl-NH-C(O)-, alkyl-NH-, (alkyl)
2-N-, alkyl-S(O)
2-NH- or alkyl-S(O)
2-, wherein the terms "alkyl, haloalkyl" are as defined above.
[0049] The term "oxo" used in the present invention refers to an =O group.
[0050] The term "cycloalkyl" used in the present invention refers to a saturated or partially
unsaturated monocyclic or polycyclic hydrocarbon group having 3 to 20 carbon atoms,
preferably 3 to 12 carbon atoms, more preferably 3 to 10 carbon atoms, and most preferably
3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyl include cyclopropyl,
cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl,
cycloheptyl, cycloheptatrienyl, cyclooctyl and the like, and preferably cyclopropyl
or cyclohexenyl. Polycyclic cycloalkyl includes a cycloalkyl having a spiro ring,
fused ring or bridged ring.
[0051] The term "aryl" used in the present invention refers to a 6 to 14 membered all-carbon
monocyclic ring or polycyclic fused ring (
i.e. each ring in the system shares an adjacent pair of carbon atoms with another ring
in the system) having a conjugated π-electron system, preferably 6 to 10 membered
aryl, more preferably phenyl and naphthyl, and most preferably phenyl.
[0052] The term "heterocyclyl" used in the present invention refers to a 3 to 20 membered
saturated or partially unsaturated monocyclic or polycyclic hydrocarbon group, wherein
one or more ring atoms are heteroatoms (for example nitrogen atoms, oxygen atoms or
sulfur atoms), with the remaining ring atoms being carbon atoms. Optionally, the ring
atoms (for example, carbon atoms, nitrogen atoms or sulfur atoms) of the cyclic structure
can be oxidized. Preferably, the heterocyclyl has 3 to 12 or 5 to 12 ring atoms wherein
1 to 4 atoms are heteroatoms, more preferably 3 to 8 ring atoms, and more preferably
5 to 6 ring atoms. Non-limited examples of monocyclic heterocyclyl include pyrrolidinyl,
piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl,
tetrahydrofuranyl and the like. Polycyclic heterocyclyl includes a heterocyclyl having
a spiro ring, fused ring or bridged ring.
[0053] The term "heteroaryl" used in the present invention refers to a 5 to 14-membered
aryl having 1 to 4 heteroatoms including O, S and N as ring atoms and the remaining
ring atoms being carbon atoms. The heteroaryl is preferably 5 to 10 membered heteroaryl,
and more preferably 5 or 6 membered heteroaryl. The specific examples of heteroaryl
include, but are not limited to furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl,
thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl,
1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl,
pyridyl, 2-pyridonyl, 4-pyridonyl, pyrimidyl, pyridazinyl, pyrazinyl, 1,2,3-triazinyl,
1,3,5-triazinyl, 1,2,4,5-tetrazinyl, azacycloheptatrienyl, 1,3-diazacycloheptatrienyl,
azacyclooctatetraenyl and the like. The heteroaryl can also be fused to the ring of
aryl, heterocyclyl or cycloalkyl.
[0054] The expression "carbon atoms, nitrogen atoms or sulfur atoms are oxidized" used in
the present invention refers to the formation of C=O, N=O, S=O or SO
2 structure.
[0055] The term "alcohol solvent" used in the present invention refers to a group derived
from a "C
1-6 alkyl" in which one or more hydrogen atoms are substituted by one or more "hydroxys",
and the terms "hydroxy" and "C
1-6 alkyl" are as defined above. Its specific examples include, but are not limited to:
methanol, ethanol, isopropanol,
n-propanol, isopentanol and trifluoroethanol.
[0056] The term "metal alkoxide" used in the present invention refers to a compound formed
by the substitution of a hydrogen of a hydroxy in an alcohol by a metal element, and
is also called a metal acid ester or a metal alkoxy compound. Metal alkoxide can be
divided into mono-metal alkoxide, bi-metal alkoxide and the like, and the metal element
can be a monovalent, divalent, trivalent or tetravalent metal. The specific examples
of metal alkoxide include, but are not limited to: lithium methoxide, sodium methoxide,
sodium ethoxide, calcium dimethoxide, aluminum tripropoxide, silicon tetraethoxide,
magnesium aluminum ethoxide, magnesium aluminum
n-butoxide and the like.
[0057] The term "stereoisomerism" used in the present invention can be classified into conformational
isomerism and configurational isomerism, while the configurational isomerism can be
further classified into
cis-trans isomerism and optical isomerism (or enantiomerism). Conformational isomerism refers
to a stereoisomerism in which an organic molecule with a certain configuration causes
different spatial arrangement modes of atoms or radicals of the molecule due to the
rotation or distortion of carbon-carbon single bonds, common examples include structures
of alkanes and cycloalkanes, such as chair conformation and boat conformation of cyclohexane.
"Optical isomers (or enantiomers)" refer to that when the compound of the present
invention contains one or more asymmetric centers, it can be used as a raceme and
a racemate mixture, a single enantiomer, a mixture of diastereomers and a single diastereomer.
The compound of the present invention has asymmetric centers, each of which can independently
generate two optical isomers. The scope of the present invention covers all possible
optical isomers and mixtures of diastereomers and pure or partially pure compounds.
If the compound of the present invention has an olefinic double bond, unless otherwise
indicated, the present invention covers a
cis-isomer and a
trans-isomer. The compound of the present invention can exist in its tautomer forms, in
which one or more double bonds shift thereby having different hydrogen attachment
points. For example, a ketone and its enol form are keto-enol tautomers. The present
invention encompasses all tautomers and mixtures thereof. All enantiomers, diastereomers,
racemes, mesomers,
cis-trans isomers, tautomers, geometric isomers, epimers and mixtures thereof are included
in the scope of the present invention.
Advantageous effects of the present invention
[0058] Compared with the prior art, the technical solution for preparing the compound of
formula (I) of the present invention has the following advantages:
- (1) The starting materials and intermediates of the present invention are different
from the prior art, the present invention has provided a synthesis method with a completely
different approach, and the starting materials and reactants are simple and easy to
purchase.
- (2) The yield is increased, the yield of the final product disclosed in the prior
art is 24.7%, while the yield of the final product of the present invention is 80%.
- (3) The post-treatment is simple, after the reaction is completed, a solid can be
obtained directly by filtration, there is no need for column chromatography purification,
and the acid treatment is avoided, therefore, the post-treatment method is conducive
to industrial production.
PREFERRED EMBODIMENTS
[0059] The present invention will be further described with reference to the following examples,
which should not be considered as limiting the scope of the present invention.
[0060] In the examples of the present invention, the experiment methods that do not specify
the specific conditions are generally conducted in accordance with conventional conditions,
or in accordance with conditions recommended by the material or product manufacturers.
The reagents without specific source are commercially available conventional reagents.
Examples
[0061] The structures of the compounds were identified by nuclear magnetic resonance (NMR)
and/or mass spectrometry (MS). NMR shifts (δ) were given in 10
-6 (ppm). NMR was determined by a Bruker AVANCE-500 machine. The solvents for determination
were deuterated reagents, and the internal standard was tetramethylsilane (TMS).
[0062] Ethyl 5-((dimethylamino)methyl)-3-(3-(6-methoxypyridazin-3-yl)ureido)-1-(4-nitrophenyl)-1
H-pyrazole-4-carboxylate (the compound of formula
(VII-1)) can be by referring to the method disclosed in Example 9 of the patent application
WO2015062391A1 (publication date: 7 May 2015),

Example 1. Preparation of 1-(4-(7-(2,6-difluorobenzyl)-3-((dimethylamino)methyl) -5-(6-methoxypyndazin-3-yl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)phenyl)-3-methoxyurea
[0063]

Step 1. Preparation of the compound of formula (VI-1-1)
[0064] The starting compound
VII-1 (90 g) was suspended in methanol (900 mL), then a 30% solution (101 g) of sodium
methoxide in methanol was added. The reaction solution was stirred in an oil bath
at 30°C for about 15 hours. After completion of the reaction, the reaction solution
was added with isopropanol (1.8 L), stirred well, cooled to room temperature, and
then freezed for 4 hours to precipitate a crystal. The mixture was filtrated to collect
a filter cake, which was pulped in acetone (320 mL) for 1.5 hours. The mixture was
cooled in an ice bath, and filtrated to collect a filter cake. The filter cake was
dried under vacuum to obtain the title product (65.9 g), yield: 81.0%, purity: 99.27%.
Step 2. Preparation of the compound of formula (IV-1)
[0065] The starting compound
VI-1-1 (1100 g) and N,N-dimethylformamide (7.0 kg) were added to a reaction flask and stirred
well, then 2,6-difluorochlorobenzyl (427.2 g) and N,N-diisopropylethylamine (926.4
g) were added. The reaction solution was warmed up to 80-110°C, and stirred for 1∼3
hours. After completion of the reaction, the reaction solution was cooled. Purified
water (30.0 kg) was added to another reaction flask, and cooled to 0-10°C. The reaction
solution was poured into the pre-cooled purified water under stirring, stirred for
0.5 h and spin-filtrated. The filter cake was washed with purified water (25.0 kg×2)
and collected.
[0066] A mixed solvent of acetone/purified water (5.2 kg of acetone/2.2 kg of purified water)
and the above filter cake were added to a reaction flask, and heated to reflux under
stirring for 0.5 h. The reaction solution was cooled to 0-10°C, stirred for 2 hours,
and filtrated. The filter cake was washed with a mixed solvent of acetone/purified
water (1.2 kg of acetone/0.5 kg of purified water), and dried to obtain a solid (1203.1
g), yield: 95%, purity: 93.64%.
Step 3. Preparation of the compound of formula (III-1)
[0067] The starting compound
IV-1 (1201.1 g) and anhydrous ethanol (4.0 kg) were added to a reaction flask. After cooling
to 0-15°C under stirring, the reaction solution was added with hydrochloric acid (5.8
kg) and stirred well. The reaction solution was added with stannous chloride dihydrate
(2400.6 g), and stirred at 15-40°C for 1-3.5 hours. After completion of the reaction,
the pH of the reaction solution was adjusted to 11-12 with a 25% (w/w) sodium hydroxide
solution (4.1 kg of sodium hydroxide in 12.3 kg of purified water) at a temperature
below 25°C. The reaction solution was spin-filtrated, and the filter cake was washed
with purified water (10.0 kg). The filter cake was dried, purified by column chromatography,
and concentrated under reduced pressure. The residue was added with
n-hexane (7.0 kg), stirred at room temperature for 0.5 h, filtrated and dried to obtain
a solid (972.6 g), yield: 90%, purity: 98.01%.
Step 4. Preparation of the compound of formula (1-1)
[0068] The starting compound
III-1 (970.6 g), tetrahydrofuran (11.5 kg), 4-nitrophenyl methoxycarbamate (423.8 g, prepared
according to the method disclosed in the patent application
WO2011090935A1), N,N-diisopropylethylamine (704.1 g) were added to a reaction flask, and the reaction
solution was stirred at 15-40°C for 16-18 hours. After completion of the reaction,
the reaction solution was cooled to 0-10°C, stirred for 2 hours and filtrated. The
filter cake was added into tetrahydrofuran (6.0 kg), stirred at room temperature for
1.5 hours and filtrated. The filter cake was washed with tetrahydrofuran (1.0 kg),
and dried to obtain a solid (807.9 g), yield: 80%.
[0069] The above resulting crude product (805.9 g) and a mixed solvent of acetone/purified
water (7897.8 g of acetone/2014.8 g of purified water) were added into a reaction
flask. The reaction solution was heated to reflux, stirred until it became clear,
and then filtrated while it was still hot. The filtrate was naturally cooled to room
temperature, and stirred for 20-24 hours. The mixture was cooled to 0-15°C, stirred
for 2 hours and filtrated. The filter cake was washed with purified water (2.5 kg×2),
and dried to obtain a solid (606.1 g), yield: 90%, purity: 99.9%.
MS m/z (ESI): 608.3 [M+1].
1H-NMR (400MHz, DMSO-
d6) δ 9.69 (s, 1H), 9.17 (s, 1H), 7.79-7.82 (d, 2H), 7.73-7.75 (d, 1H), 7.68-7.70 (d,
2H), 7.42-7.45 (d, 1H), 7.37-7.41 (m, 1H), 7.06-7.12 (m, 2H), 5.28 (s, 2H), 4.09 (s,
3H), 3.67 (s, 2H), 3.66 (s, 3H), 2.17 (s, 6H).
Example 2. The compound 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methy 1)-3-(6-methoxygyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea (formula (1-2)) was prepared by referring to
the method in Example 1 above
[0070]

Example 3. The compound 1-(4-(5-((benzyl(methyl)amino)methyl)-1-(2,6-difluor obenzyl)-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea (formula (I-3)) was prepared by referring to
the method in Example 1 above
[0071]

1. A method for preparing a compound of formula (I) or a stereoisomer thereof,
characterized in that the method comprises a step of reacting a compound of formula (III), a salt thereof
or a stereoisomer thereof with a compound of formula (II) or a salt thereof to obtain
the compound of formula (I),

wherein,
when G is N, D is C, and E is -CH-;
when G is C, D and E are N, or D is C and E is S;
R1 is selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl
and -OR5, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently
and optionally further substituted by one or more substituents selected from the group
consisting of halogen, cyano, nitro, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl,
cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR5, -C(O)OR5, -OC(O)R5, -NHS(O)mR5, -C(O)R5, -NHC(O)R5, -NHC(O)OR5, -NR6R7, -OC(O)NR6R7, -C(O)NR6R7, -NHC(O)NHR5 and -NHC(O)NHOR5;
R2 is alkyl, wherein the alkyl is further substituted by one or more substituents selected
from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl
are optionally further substituted by one or more substituents selected from the group
consisting of halogen, alkyl, haloalkyl, cyano, nitro, -C(O)OR5, -C(O)NR6R7, -OC(O)NR6R7, -OR5, -NHS(O)mR5, -NHC(O)R5 and -NR6R7, wherein the haloalkyl is preferably trifluoromethyl;
R3 is alkyl;
R4 is selected from the group consisting of hydrogen, cycloalkyl, heterocyclyl, aryl,
heteroaryl, -OR5, -NR6R7 and -NR6S(O)mR5, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally
further substituted by one or more substituents selected from the group consisting
of halogen, oxo, alkyl, haloalkyl, hydroxyalkyl, -OR5, -C(O)OR5, -OC(O)R5, -NR7S(O)mR5, -S(O)mR5, -C(O)R5 and -NHC(O)R5;
R5 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclyl,
aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl
are each independently and optionally further substituted by one or more substituents
selected from the group consisting of alkyl, halogen, hydroxy, alkoxy, haloalkoxy,
cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxy and alkoxycarbonyl;
R6 and R7 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl,
heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl
and heteroaryl are each independently and optionally further substituted by one or
more substituents selected from the group consisting of alkyl, halogen, hydroxy, alkoxy,
haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxy and alkoxycarbonyl;
or, R6 and R7 together with the nitrogen atom to which they are attached form a heterocyclyl, wherein
the heterocyclyl contains one or more heteroatoms selected from the group consisting
of N, O and S(O)m, and the heterocyclyl is optionally further substituted by one or more substituents
selected from the group consisting of alkyl, halogen, hydroxy, alkoxy, haloalkoxy,
cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxy and alkoxycarbonyl;
Ra is alkyl, wherein the alkyl is optionally further substituted by one or more substituents
selected from the group consisting of alkyl, halogen, hydroxy, alkoxy, cycloalkyl,
heterocyclyl, aryl, heteroaryl, carboxy and alkoxycarbonyl;
m is 0, 1 or 2; and
n is 1, 2, 3 or 4.
2. The method according to claim 1,
characterized in that the method also comprises steps of:

wherein, n, D, E, G, R
1, R
2, R
3, and R
4 are as defined in claim 1;
the compound of formula (VI) is a mono-metal alkoxide or a bi-metal alkoxide, M is
selected from the group consisting of monovalent metal cation, divalent metal cation,
trivalent metal cation and tetravalent metal cation, preferably sodium ion, potassium
ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion, copper ion,
zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon ion, and
more preferably sodium ion; and X is halogen, and preferably fluorine, chlorine or
bromine.
3. The method according to claim 2,
characterized in that the method also comprises a step of:
wherein, n, D, E, G, R1, R3, and R4 are as defined in claim 1;
M is as defined in claim 2; and
Rb is alkyl.
4. A method for preparing a compound of formula (1-1),
characterized in that the method is as follows:
5. The method according to claim 4,
characterized in that the method also comprises steps of:

the compound of formula (VI-1) is a mono-metal alkoxide or a bi-metal alkoxide, M
is selected from the group consisting of monovalent metal cation, divalent metal cation,
trivalent metal cation and tetravalent metal cation, preferably sodium ion, potassium
ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion, copper ion,
zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon ion, and
more preferably sodium ion.
6. The method according to claim 5,
characterized in that the method also comprises a step of:
7. The method according to claim 6, characterized in that no acid is added in the post-treatment step of the method, the acid is selected from
the group consisting of an organic acid and an inorganic acid, the organic acid is
preferably trifluoroacetic acid or acetic acid, and the inorganic acid is preferably
hydrochloric acid.
8. A compound of formula (VI)

or a salt thereof or a stereoisomer thereof,
wherein, n, D, E, G, R
1, R
3, and R
4 are as defined in claim 1;
the compound of formula (VI) is a mono-metal alkoxide or a bi-metal alkoxide, M is
selected from the group consisting of monovalent metal cation, divalent metal cation,
trivalent metal cation and tetravalent metal cation, preferably sodium ion, potassium
ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion, copper ion,
zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon ion, and
more preferably sodium ion.
9. The compound according to claim 8, being
10. The compound according to claim 9, being
11. A method for preparing a compound of formula (VI),
characterized in that the method is as follows:

wherein, n, D, E, G, R
1, R
3, and R
4 are as defined in claim 1;
R
b is alkyl;
the compound of formula (VI) is a mono-metal alkoxide or a bi-metal alkoxide, M is
selected from the group consisting of monovalent metal cation, divalent metal cation,
trivalent metal cation and tetravalent metal cation, preferably sodium ion, potassium
ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion, copper ion,
zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon ion, and
more preferably sodium ion.
12. A method for preparing a compound of formula (VI-1),
characterized in that the method is as follows:

wherein, the compound of formula (VI-1) is a mono-metal alkoxide or a bi-metal alkoxide,
M is selected from the group consisting of monovalent metal cation, divalent metal
cation, trivalent metal cation and tetravalent metal cation, preferably sodium ion,
potassium ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion,
copper ion, zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon
ion, and more preferably sodium ion.
13. The method according to claim 12, characterized in that no acid is added in the post-treatment step of the method, the acid is selected from
the group consisting of an organic acid and an inorganic acid, the organic acid is
preferably trifluoroacetic acid or acetic acid, and the inorganic acid is preferably
hydrochloric acid.
14. The method according to claim 13,
characterized in that the method is as follows:
15. A method for preparing a compound of formula (1-1),
characterized in that the method is as follows:
16. The method according to claim 15, characterized in that no acid is added in the post-treatment step of the method for preparing the compound
of formula (VI-1) from the compound of formula (VII-1), the acid is selected from
the group consisting of an organic acid and an inorganic acid, the organic acid is
preferably trifluoroacetic acid or acetic acid, and the inorganic acid is preferably
hydrochloric acid.
17. A method for preparing a compound of formula (1-2),
characterized in that the method is as follows:
18. The method according to claim 17,
characterized in that the method also comprises steps of:

the compound of formula (VI-2) is a mono-metal alkoxide or a bi-metal alkoxide, M
is selected from the group consisting of monovalent metal cation, divalent metal cation,
trivalent metal cation and tetravalent metal cation, preferably sodium ion, potassium
ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion, copper ion,
zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon ion, and
more preferably sodium ion.
19. The method according to claim 18,
characterized in that the method also comprises a step of:
20. The method according to claim 19, characterized in that no acid is added in the post-treatment step of the method, the acid is selected from
the group consisting of an organic acid and an inorganic acid, the organic acid is
preferably trifluoroacetic acid or acetic acid, and the inorganic acid is preferably
hydrochloric acid.
21. A method for preparing a compound of formula (1-2),
characterized in that the method is as follows:
22. The method according to claim 21, characterized in that no acid is added in the post-treatment step of the method for preparing the compound
of formula (VI-2-1) from the compound of formula (VII-2), the acid is selected from
the group consisting of an organic acid and an inorganic acid, the organic acid is
preferably trifluoroacetic acid or acetic acid, and the inorganic acid is preferably
hydrochloric acid.
23. A method for preparing a compound of formula (I-3),
characterized in that the method is as follows:
24. The method according to claim 23,
characterized in that the method also comprises steps of:

the compound of formula (VI-3) is a mono-metal alkoxide or a bi-metal alkoxide, M
is selected from the group consisting of monovalent metal cation, divalent metal cation,
trivalent metal cation and tetravalent metal cation, preferably sodium ion, potassium
ion, lithium ion, calcium ion, magnesium ion, barium ion, aluminum ion, copper ion,
zinc ion, zirconium ion, germanium ion, boron ion, titanium ion or silicon ion, and
more preferably sodium ion.
25. The method according to claim 24,
characterized in that the method also comprises a step of:
26. The method according to claim 25, characterized in that no acid is added in the post-treatment step of the method, the acid is selected from
the group consisting of an organic acid and an inorganic acid, the organic acid is
preferably trifluoroacetic acid or acetic acid, and the inorganic acid is preferably
hydrochloric acid.
27. A method for preparing a compound of formula (1-3),
characterized in that the method is as follows:
28. The method according to claim 27, characterized in that no acid is added in the post-treatment step of the method for preparing the compound
of formula (VI-3-1) from the compound of formula (VII-3), the acid is selected from
the group consisting of an organic acid and an inorganic acid, the organic acid is
preferably trifluoroacetic acid or acetic acid, and the inorganic acid is preferably
hydrochloric acid.
29. A method for preparing a pharmaceutically acceptable salt of a compound of formula
(1-1), formula (1-2) or formula (1-3), comprising the step(s) according to any one
of claims 1 to 7, 15 to 16, 17 to 22 and 23 to 28, and a step of reacting the compound
of formula (1-1), formula (1-2) or formula (1-3) with an acid to obtain the pharmaceutically
acceptable salt thereof, wherein the acid is selected from the group consisting of
an organic acid and an inorganic acid, and preferably an organic acid; the organic
acid is selected from the group consisting of acetic acid, maleic acid, fumaric acid,
methanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid, and preferably acetic acid; and the inorganic acid is selected
from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid and
phosphoric acid.